Phase 3 Readout

RPRX: Phase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma

Name: Phase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma
Start: 2026-06-15
End: 2026-06-15

June 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 15, 2026
Company: Royalty Pharma plc (RPRX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma

June 15, 2026

RPRX overview →

Company: Royalty Pharma plc (RPRX)
Indication: Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma